Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
Data ReadoutpositiveZiiheratislelizumabtrastuzumabPositive
AI Analysis
Summary
Ziihera (zanidatamab-hrii) plus chemotherapy demonstrated statistically significant overall survival benefit compared to trastuzumab plus chemotherapy in the HERIZON-GEA-01 trial for first-line HER2+ advanced gastric/esophageal adenocarcinoma. The positive data reinforce Ziihera as the new standard-of-care HER2-targeted backbone therapy in this indication.
Clinical Trial Data
Phase
Phase_3
Primary Endpoint
Met
Outcome Details
Ziihera plus chemotherapy demonstrated statistically significant overall survival benefit versus trastuzumab plus chemotherapy in first-line HER2+ advanced GEA. HERIZON-GEA-01 trial showed improved OS hazard ratio with Ziihera plus tislelizumab and chemotherapy combination.
Importance:8/10
Sentiment:
0.85
HER2+gastric canceroverall survivalfirst-line treatmentFDA approvedclinical trial positive
Related Companies
Read the original article
Published by PR Newswire Pharma on August 31, 2026 10:00 AM